Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer

Journal of Korean Medical Science

Volumn 26, Issue 5, 2011, Pages 625-630

  Kim, Hye Ran ^a   Oh, In Jae ^b   Shin, Myung Geun ^b   Park, Joon Seok ^c   Choi, Hyun Jung ^b   Ban, Hee Jung ^b   Kim, Kyu Sik ^b   Kim, Young Chul ^b   Shin, Jong Hee ^b   Ryang, Dong Wook ^b   Suh, Soon Pal ^b  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Abbott Diagnostics   (South Korea)

Author keywords

Plasma; Pro gastrin releasing peptide (31 98); Serum; Small cell lung carcinoma

Indexed keywords

PEPTIDE FRAGMENT; PRO GASTRIN RELEASING PEPTIDE (31 98); PRO-GASTRIN-RELEASING PEPTIDE (31-98); RECOMBINANT PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 79955630045     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.5.625     Document Type: Article

References (18)

1. Paik KH, Park YH, Ryoo BY, Yang SH, Lee JC, Kim CH, Ki SS, Kim JM, Park MJ, Ahn HJ, Choi W, Chung JH. Prognostic value of immunohisto-chemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J Korean Med Sci 2006; 21: 35-9.
2. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994; 54: 2136-40.
3. Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 1983; 43: 3932-9.
4. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 1996; 73: 1227-32.
5. Molina R, Filella X, Augé JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004; 37: 505-11.
6. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. Anticancer Res 1999; 19: 2673-8.
7. Molina R, Auge JM, Alicarte J, Filella X, Viñolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumour Biol 2004; 25: 56-61.
8. Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000; 27: 159-67.
9. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y, Kodama T. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995; 86: 698-705.
10. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, Makimoto T, Ishihara S, Saito R, Mori M. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999; 57: 143-8.
11. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997; 3: 123-7.
12. Kuwabara M, Shibata N, Ariyoshi Y. Lung cancer: progress in diagnosis and treatment. I. Diagnosis and physiopathology: 4. Progress in the study of tumor markers. Nippon Naika Gakkai Zasshi 1997; 86: 20-6.
13. Banfi G, Parma P, Pontillo M. Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator. Clin Chem 1997; 43: 2430-1.
14. Yoshimura T, Fujita K, Kawakami S, Takeda K, Chan S, Beligere G, Dowell B. Stability of Pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol 2008; 29: 224-30.
15. Nordlund MS, Bjerner J, Warren DJ, Nustad K, Paus E. Pro-gastrin-releasing peptide: stability in plasma/serum and upper reference limit. Tumour Biol 2008; 29: 204-10.
16. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K. Enzyme immunoassay of immunoreactive Pro-gastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995; 41: 537-43.
17. Gruber C, Hatz R, Reinmiedl J, Nagel D, Stieber P. CEA, cyfra 21-1, NSE, and proGRP in the diagnosis of lung cancer: a multivariate approach. J Lab Med 2008; 32: 361-71.
18. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. Te diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009; 29: 4827-32.